BJC：HIF-1α预测膀胱癌受益于放疗-CON联合治疗

　　
　　来自曼彻斯特大学的团队发现膀胱肿瘤患者有较高水平的蛋白质HIF-1α，更有可能受益于一种治疗方法，即在放疗的同时给予患者混和氧（95％O2、5％CO2的混合气体）和烟酰胺片。这种治疗方法被称为"CON"，能使放射放疗更有效。

　　通过比较，单独放疗或放疗与CON联合治疗患者肿瘤组织样本中HIF-1α的水平，研究人员发现该蛋白能预测哪些患者受益于CON。当患者接受放疗和CON，高浓度的蛋白质与疾病更好的生存有关联。低蛋白水平患者并没有受益于CON与组合放射治疗。

　　doi:10.1038/bjc.2014.315

　　PMC:

　　PMID:

　　Expression hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer

　　Hunter, BA et al.

　　Background:

　　The addition of carbogen and nicotinamide (CON) to radiotherapy (RT) improves overall survival in invasive bladder cancer. We explored whether expression of the hypoxia marker hypoxia-inducible factor-1α (HIF-1α) alone or in combination with other markers predicted benefit from CON.

　　Methods:

　　A retrospective study was carried out using material from patients with high-grade invasive bladder carcinoma enrolled in the BCON phase III trial of RT alone or with CON (RT+CON). HIF-1α expression was studied in 137 tumours using tissue microarrays and immunohistochemistry. Data were available from other studies for carbonic anhydrase IX and glucose transporter 1 protein and gene expression and tumour necrosis.

　　Results:

　　Patients with high HIF-1α expression had improved 5-year local relapse-free survival with RT+CON (47%) compared with RT alone (21%; hazard ratio (HR) 0.48, 95% CI 0.26-0.8, P=0.02), no benefit was seen with low HIF-1α expression (HR 0.81, 95% CI 0.43-1.50, P=0.5). Combinations of markers including necrosis also predicted benefit but did not improve on prediction using necrosis alone.

　　Conclusions:

　　HIF-1α may be used to predict benefit from CON in patients with bladder cancer but does not improve on use of necrosis.

　　膀胱癌如何治疗？膀胱癌的治疗药物可以选择：复方皂矾丸、艾诺克、西黄胶囊等药物进行辅助治疗。

　　详情请致电我们的客服垂询：400-101-6868。如需购买复方皂矾丸、艾诺克、西黄胶囊，可到临近门店。广州肿瘤店地址为：广州市越秀区先烈南路21号之一（中山大学肿瘤医院中门斜对面）。通过GSP质量认证的药房，获"广州市药品经 营诚信企业"和工商局颁发的"消费者信得过商家"称号。门店电话：020-87303808。

　　肿瘤科药师温馨提醒：膀胱癌的发病是一个多因素混合、多基因参与、多步骤形成的过程，异常基因型的积累加上外在环境的作用终导致恶性表型的出现。